Pharmacogenetics of therapies in rheumatoid arthritis: An update

Rheumatoid arthritis (RA) is a systemic autoimmune inflammatory arthritis. Despite many treatment advances, achieving remission or low-disease activity in RA remains challenging, often requiring trial and error approaches with numerous medications. Precision medicine, particularly pharmacogenomics,...

Full description

Saved in:
Bibliographic Details
Published inBest practice & research. Clinical rheumatology p. 101974
Main Authors Babiker-Mohamed, Mohamed H., Bhandari, Sambhawana, Ranganathan, Prabha
Format Journal Article
LanguageEnglish
Published Netherlands Elsevier Ltd 20.07.2024
Subjects
Biologics
DMARDs
Pharmacogenetics
Rheumatoid arthritis
Pharmacogenetics
DMARDs
Rheumatoid arthritis
Biologics
Online AccessGet full text

Cover

More Information
Summary:Rheumatoid arthritis (RA) is a systemic autoimmune inflammatory arthritis. Despite many treatment advances, achieving remission or low-disease activity in RA remains challenging, often requiring trial and error approaches with numerous medications. Precision medicine, particularly pharmacogenomics, explores how genetic factors influence drug response in individual patients, and incorporates such factors to develop personalized treatments for individual patients. Genetic variations in drug-metabolizing enzymes, transporters, and targets may contribute to inter-individual differences in drug efficacy and toxicity. Advancements in molecular sequencing have allowed rapid identification of such variants, including single nucleotide polymorphisms (SNPs). This review highlights recent major findings in the pharmacogenetics of therapies in RA, focusing on key genes and SNPs to provide insights into current trends and developments in this field.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
ISSN:1521-6942
1532-1770
1532-1770
DOI:10.1016/j.berh.2024.101974